Latest Comments

Amgen and Array BioPharma partnership: creating waves in autoimmune disorder market

Amgen and Array BioPharma partnership: creating waves in autoimmune disorder market

Fighting obesity: Past and future treatments

Fighting obesity: Past and future treatments

Tensions Rise as UK Pharma Industry Takes Government to Court

Tensions Rise as UK Pharma Industry Takes Government to Court

A vaccine for Lyme disease – second time lucky?

A vaccine for Lyme disease – second time lucky?

Breakthroughs for orphan designated hematological drugs could earn big revenues

Breakthroughs for orphan designated hematological drugs could earn big revenues

Gilead looks to maintain dominance in HIV with its novel STR

Gilead looks to maintain dominance in HIV with its novel STR

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Hemophilia gene therapies impress, but pricing doubts remain

Hemophilia gene therapies impress, but pricing doubts remain

Merck’s Keytruda stumbles in multiple myeloma

Merck’s Keytruda stumbles in multiple myeloma

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

Novel Approaches to US Cancer Research Funding on the Horizon

Novel Approaches to US Cancer Research Funding on the Horizon

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: New Hope for Multiple Myeloma Patients

EHA 2017: New Hope for Multiple Myeloma Patients

EHA 2017: BCl-2 as an Emerging Target for AML

EHA 2017: BCl-2 as an Emerging Target for AML

EULAR 2017: Considerations after first TNF-failure in RA

EULAR 2017: Considerations after first TNF-failure in RA

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

The anti-vaccination movement and public health

The anti-vaccination movement and public health

Niche is the new normal: the growth of the orphan drugs market

Niche is the new normal: the growth of the orphan drugs market

COPD severity differs by severity system used

COPD severity differs by severity system used

NeuPSIG 2017: personalized treatments may hold the key to treatment progress in neuropathic pain

NeuPSIG 2017: personalized treatments may hold the key to treatment progress in neuropathic pain